Papers from every journal, all in one place. Launch research agents to watch your topics.
While very interesting that 91% had positive CVB serologies, prevalence is probably not the best term to use, as to be included in the analysis, patients had to have sarcoidosis and available CVB testing. Prevalence could be defined if all sarcoidosis patients had CVB testing.
Open HeartDonnelly et al.
ESC Congress 2026 · SWITCH SWEDEHEART
Great study pioneering to use of cluster randomization in registries to test different treatment strategies in real life. Very useful cost-effective model when implementing novel treatment strategies in the real life setting. The comparison of the strategies "prasugrel first choice" vs "ticagrelor first choice" turned out neutral on efficacy - safety difficult to evaluate in this setting. Good to have two similar alternatives to tailor to different patients and settings.
New England Journal of MedicineElmir Ömerovic et al.
Interventional Cardiologist · Charles University and University Hospital Kralovske Vinohrady
Using the blueprint already employed for heart attacks, we were able to demonstrate that specialised interventional treatment can be delivered in tertiary care centres across our national network. This may pave the way for an improved, standardised approach to the treatment of pulmonary embolism, reducing the acute risks that patients face.
New England Journal of MedicineKroupa et al.
ESC Congress 2026 · HIS Alternative II
this is an interesting first take. A well done study but limited by duration of follow up and sample size. It does seem to indicate when the procedure is well done, actually both procedures well done there may not be that much difference between both techniques.
JACC. Clinical electrophysiologyMichael Vinther et al.
Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.
New England Journal of MedicineHausleiter et al.
Lead Researcher · Monash University School of Public Health and Preventive Medicine
A notable finding is that the lower incidence of major, nonfatal cardiovascular events with atorvastatin than with placebo did not result in a corresponding improvement in disability-frees survival. Explanations for this result might include the fact that 80% of the deaths in the trial were from non-cardiovascular causes.
New England Journal of MedicineZoungas et al.
The key impact on clinical practice is that the level of evidence about this population was actually very low, and this is the first [randomized controlled trial] to support that DOAC therapy can give benefit to this patient population.
New England Journal of MedicineKim et al.
Cardiologist · Copenhagen University Hospital
It seems that from POET I and POET II we have challenged dogmas showing that less intensive antibiotic therapy after stabilization is superior and safe. And we think that defining the stabilization point is a kind of personalizing endocarditis treatment.
New England Journal of MedicineBundgaard et al.
ESC Congress 2026 · AMUNDSEN
Why didn’t achieving an LDL-C of 16mg/dl 6 weeks after MI and an LDL-C difference between groups of 40mg/dl at week 6 with the aforementioned rationale translate into significant clinical benefits at 1 year?
JAMAGilles Montalescot et al.
Professor of Emergency Medicine · The Usher Institute, University of Edinburgh
Although immediate ECG monitoring did not reduce recurrent fainting, it enabled earlier identification of serious cardiac rhythm disorders, allowing patients to receive treatment much sooner, reducing uncertainty and anxiety, and potentially preventing avoidable deaths.
New England Journal of MedicineReed et al.
Expert commentary · @gbiondizoccai
In the 986-patient TAVI PCI RCT, a strategy of TAVI before PCI yielded similar outcome to a strategy of PCI before TAVI at 1 year in patients with both aortic stenosis and CAD (25% MVD) https://t.co/8d0elI9CeM #CAD #PCI #TAVI #TAVR @NEJM @escardio https://t.co/OEZFeSNXLq
New England Journal of MedicineStähli et al.
Cardiologist · Oregon Health & Science University
Results from the ACACIA-HCM trial provide really positive news for patients with symptomatic non-obstructive HCM. For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.
New England Journal of MedicineMasri et al.
ESC Congress 2026 · STAREE
Cardiology
Key Question
Should statin initiation in older adults be individualized rather than age-based?
Individualized, considering function (and CAC), not age to identify risk and time to benefit. CAC of zero in up to 18% of primary prevention age 75+ population.
New England Journal of MedicineSophia Zoungas et al.
Cardiologist · Nanjing First Hospital
Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure. … Additional long-term follow-up will be important to determine whether the observed mid-term improvements translate into sustained reductions in mortality and hospitalization for HF.
New England Journal of MedicineZhang et al.
BHF Professor of Cardiology, University of Edinburgh · University of Edinburgh
Our findings provide strong evidence that patients who have had a heart attack excluded do not benefit from early outpatient CTCA scans. Once we are confident that they haven't had a heart attack, we can reassure these patients that their future risk is low and send them home.
New England Journal of MedicineLee et al.